List of works - Einat Brill-Almon

739 - A Novel Orally Administered Recombinant Anti-TNF Alpha Fusion Protein for the Treatment of Mild to Moderate Ulcerative Colitis: Results of a Phase 2A Clinical Trial Showing Promising Results

scholarly article published in May 2018

A Multicenter, Double-Blind, Randomized Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Patients with Gaucher Disease. ⬇️

scholarly article

A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with i

scientific article published on 18 June 2014

A plant-derived recombinant human glucocerebrosidase enzyme--a preclinical and phase I investigation

scientific article published in 2009

An oral administration of a recombinant anti-TNF fusion protein is biologically active in the gut promoting regulatory T cells: Results of a phase I clinical trial using a novel oral anti-TNF alpha-based therapy

scientific article published on 6 April 2017

Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase

scientific article published on 22 April 2016

Ex vivo transduction of human dermal tissue structures for autologous implantation production and delivery of therapeutic proteins

scientific article

Human erythropoietin gene therapy for patients with chronic renal failure

scientific article published on 29 March 2005

Improving the accuracy of MRI spleen and liver volume measurements: A phase III Gaucher disease clinical trial setting as a model ⬇️

scientific article published on November 17, 2010

Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naïve patients with Gaucher disease

scientific article published on 19 March 2016

Novel Orally Administered Recombinant Anti-TNF Alpha Fusion Protein for the Treatment of Ulcerative Colitis: Results From a Phase 2a Clinical Trial

scientific article published on 03 June 2020

Once every 4 weeks - 2 mg/kg of pegunigalsidase alfa for treating Fabry disease Preliminary results of a phase 3 study

scholarly article

Pegunigalsidase alfa for the treatment of Fabry disease: Preliminary results from a phase III open label, switch over study from agalsidase alfa

scholarly article

Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial

scientific article published on 08 April 2019

Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease

scientific article

Preclinical and first-in-human evaluation of PRX-105, a PEGylated, plant-derived, recombinant human acetylcholinesterase-R

scientific article published on 04 June 2015

Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system

scientific article

Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease

scientific article published on 7 November 2014

Zimran A, Brill-Almon E, Chertkoff R, et al. Pivotal trial with plant cell?expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood. 2011;118(22):.

scientific article published in May 2012

List of works by Einat Brill-Almon

739 - A Novel Orally Administered Recombinant Anti-TNF Alpha Fusion Protein for the Treatment of Mild to Moderate Ulcerative Colitis: Results of a Phase 2A Clinical Trial Showing Promising Results

A Multicenter, Double-Blind, Randomized Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Patients with Gaucher Disease. ⬇️

A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with i

A plant-derived recombinant human glucocerebrosidase enzyme--a preclinical and phase I investigation

An oral administration of a recombinant anti-TNF fusion protein is biologically active in the gut promoting regulatory T cells: Results of a phase I clinical trial using a novel oral anti-TNF alpha-based therapy

Enzyme replacement therapy with taliglucerase alfa: 36-month safety and efficacy results in adult patients with Gaucher disease previously treated with imiglucerase

Ex vivo transduction of human dermal tissue structures for autologous implantation production and delivery of therapeutic proteins

Human erythropoietin gene therapy for patients with chronic renal failure

Improving the accuracy of MRI spleen and liver volume measurements: A phase III Gaucher disease clinical trial setting as a model ⬇️

Long-term efficacy and safety results of taliglucerase alfa up to 36 months in adult treatment-naïve patients with Gaucher disease

Novel Orally Administered Recombinant Anti-TNF Alpha Fusion Protein for the Treatment of Ulcerative Colitis: Results From a Phase 2a Clinical Trial

Once every 4 weeks - 2 mg/kg of pegunigalsidase alfa for treating Fabry disease Preliminary results of a phase 3 study

Pegunigalsidase alfa for the treatment of Fabry disease: Preliminary results from a phase III open label, switch over study from agalsidase alfa

Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1-year Phase 1/2 clinical trial

Pivotal trial with plant cell-expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease

Preclinical and first-in-human evaluation of PRX-105, a PEGylated, plant-derived, recombinant human acetylcholinesterase-R

Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system

Safety and efficacy of two dose levels of taliglucerase alfa in pediatric patients with Gaucher disease

Zimran A, Brill-Almon E, Chertkoff R, et al. Pivotal trial with plant cell?expressed recombinant glucocerebrosidase, taliglucerase alfa, a novel enzyme replacement therapy for Gaucher disease. Blood. 2011;118(22):.